ATE290862T1 - Anti-androgene und verfahren zur behandlung von krankheiten - Google Patents

Anti-androgene und verfahren zur behandlung von krankheiten

Info

Publication number
ATE290862T1
ATE290862T1 AT00905748T AT00905748T ATE290862T1 AT E290862 T1 ATE290862 T1 AT E290862T1 AT 00905748 T AT00905748 T AT 00905748T AT 00905748 T AT00905748 T AT 00905748T AT E290862 T1 ATE290862 T1 AT E290862T1
Authority
AT
Austria
Prior art keywords
androgens
methods
treating diseases
diseases
gonadotropins
Prior art date
Application number
AT00905748T
Other languages
English (en)
Inventor
Dennis Murphy
Patrick J Wier
Giuseppe Arnaldo Mari Giardina
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE290862T1 publication Critical patent/ATE290862T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AT00905748T 1999-01-25 2000-01-25 Anti-androgene und verfahren zur behandlung von krankheiten ATE290862T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11705999P 1999-01-25 1999-01-25
PCT/US2000/001956 WO2000043008A1 (en) 1999-01-25 2000-01-25 Anti-androgens and methods for treating disease

Publications (1)

Publication Number Publication Date
ATE290862T1 true ATE290862T1 (de) 2005-04-15

Family

ID=22370778

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00905748T ATE290862T1 (de) 1999-01-25 2000-01-25 Anti-androgene und verfahren zur behandlung von krankheiten

Country Status (6)

Country Link
EP (1) EP1146873B1 (de)
JP (1) JP2002535274A (de)
AT (1) ATE290862T1 (de)
DE (1) DE60018707T2 (de)
ES (1) ES2237408T3 (de)
WO (1) WO2000043008A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
CN1551878B (zh) 2001-09-06 2011-08-10 先灵公司 用于治疗雄激素依赖性疾病的3型17β-羟基类固醇脱氢酶抑制剂
PE20030705A1 (es) 2001-10-17 2003-08-21 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
SI2552920T1 (sl) 2010-04-02 2017-07-31 Ogeda Sa Nove nk-3 receptor selektivne antagonist spojine, farmacevtski sestavki in postopki za uporabo pri nk-3 receptor posredovanih motnjah
KR102049534B1 (ko) 2011-10-03 2019-11-27 오게다 에스.에이. 선택적 NK-3 수용체 길항제로서의 신규한 키랄 N-아실-5,6,7,(8-치환된)-테트라히드로-[1,2,4]트리아졸로[4,3-a]피라진, 의약 조성물, NK-3 수용체 매개 질환에 사용하는 방법 및 그의 키랄 합성법
HUE035870T2 (hu) 2013-03-29 2018-05-28 Ogeda S A N-acil-(3- szubsztituált)-(8- szubsztituált)-5,6-dihidro-[1,2,4]triazolo[4,3-A]pirazinok mint szelektív NK-3 receptor antagonisták, gyógyászati készítmény, eljárások NK-3 receptor által közvetített rendellenességek során történõ alkalmazásra
US10183948B2 (en) 2013-03-29 2019-01-22 Ogeda Sa N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
JP6275241B2 (ja) 2013-03-29 2018-02-07 オゲダ エス．エー． 選択的ＮＫ−３受容体拮抗薬としての新規なＮ−アシル−（３位置換）−５，６，７，８−テトラヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、その医薬組成物、ＮＫ−３受容体媒介性障害で使用する方法
WO2014154897A1 (en) 2013-03-29 2014-10-02 Euroscreen Sa NOVEL N-ACYL-(3-SUBSTITUTED)-(8-METHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
US9475773B2 (en) 2013-04-19 2016-10-25 Astrazeneca Ab NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
GB201315846D0 (en) 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes
WO2017072629A1 (en) * 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
WO2023278843A2 (en) 2021-07-02 2023-01-05 Acer Therapeutics, Inc. Solid forms of osanetant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120840A (en) * 1990-08-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. 4-amino-4-ene-steroids and their use as 5α-reductase inhibitors
WO1993023053A1 (en) * 1992-05-21 1993-11-25 Endorecherche Inc. INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY
GB9216329D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives
US5380728A (en) * 1993-02-10 1995-01-10 Merck & Co., Inc. Aldehyde metabolite of 17β-N-monosubstituted-carbamoyl-4-aza-5α-a
PL186665B1 (pl) * 1994-05-27 2004-02-27 Smithkline Beecham Spa Pochodne chinoliny jako antagoniści receptorów NKtachykininy, sposób ich wytwarzania, kompozycja farmaceutyczna zawierająca pochodne chinoliny oraz ich zastosowanie
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
IT1275594B1 (it) * 1995-07-21 1997-08-06 Pharmacia S P A Ora Pharmacia Epimeri del (22rs)-n-(1,1,1-trifluoro-2-fenilprop-2-il)-3-osso -4-aza-5alfa-androst-1-ene-17beta-carbossammide

Also Published As

Publication number Publication date
JP2002535274A (ja) 2002-10-22
DE60018707T2 (de) 2006-02-09
DE60018707D1 (de) 2005-04-21
EP1146873B1 (de) 2005-03-16
WO2000043008A1 (en) 2000-07-27
EP1146873A1 (de) 2001-10-24
ES2237408T3 (es) 2005-08-01
EP1146873A4 (de) 2003-03-26

Similar Documents

Publication Publication Date Title
ATE290862T1 (de) Anti-androgene und verfahren zur behandlung von krankheiten
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
NO20052928L (no) Nye kjemiske forbindelser
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
ATE360417T1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE60214179D1 (de) IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
ATE267013T1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit
DE60228583D1 (de) Verfahren und materialien für die behandlung des testosteron-mangels bei männern
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE60312474D1 (de) 5-ht3-rezeptorantagonisten und verwendungsverfahren
DE60220385D1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
ATE551054T1 (de) Verfahren und zusammensetzungen zur behandlung von nephrogenem diabetes insipidus
ATE337787T1 (de) Exemestan zur behandlung von hormonabhängigen störungen
ATE359816T1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
ATE410235T1 (de) Behandlung von ballastwasser
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE385789T1 (de) Verwendung von einem aldosteronantagonist zur behandlung und vorbeugung von aldosteron- vermittelten pathogenen zuständen
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties